Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a typical, first generation antipsychotic with general properties similar to those of chlorpromazine, that is used for the treatment of schizophrenia and other psychoses. Oral or intramuscular administration in two or three daily doses.
No data on transfer into breastmilk are available.
Its high percentage of protein binding and moderately high molecular weight make it unlikely that significant quantities will pass into breast milk.
Product with very few bibliographical references and marketed in few countries.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Parikh 2014, Klinger 2013), especially during the neonatal period and in cases of prematurity.
See below the information of this related product: